A to Z: Drugs in Highlight: V is for VENCLEXTA®
News, A to Z Feature
30/04/2025
Our A to Z series highlights VENCLEXTA® (venetoclax) from AbbVie, a medication used to treat both chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML). This article explores its mechanism of action, clinical applications, and the patent protection surrounding this important drug.
Read more
The Role of IP Royalties in Mitigating the Financial Effects of Tariffs
News
29/04/2025
Tariffs are making headlines, but what exactly are they and do they affect intellectual property? Discover how these taxes on imported goods differ from IP royalties, explore the indirect link between them in trade disputes, and learn potential strategies for businesses to mitigate tariff costs by understanding the treatment of intangible asset payments.
Read more
Protecting Your Innovation: An Intellectual Property (IP) Breakfast for Businesses and Innovators
Events, News, Team news
27/04/2025
Is your Intellectual Property a hidden asset or a vulnerable liability? Discover how to turn your ideas into a competitive advantage at our Intellectual Property (IP) Breakfast for Business Growth. Join us on Wednesday, May 28th, at York St John University in York for light bites, refreshments and to learn more about how IP is integral to your business growth.
Read more
A to Z: Drugs in Highlight: U is for UPTRAVI®
News, A to Z Feature
24/04/2025
This series continues to explore the fascinating world of pharmaceuticals. Next up is U is for UPTRAVI. UPTRAVI® (from Johnson & Johnson) is used to treat pulmonary arterial hypertension (PAH) in adults.
Read more
A to Z: Drugs in Highlight: T is for TECFIDERA®
News, A to Z Feature
17/04/2025
This series continues to explore the fascinating world of pharmaceuticals. Next up is T is for TECFIDERA. TECFIDERA (from Biogen) is a disease modifying therapy used for treating people with relapsing-remitting Multiple Sclerosis (MS).
Read more
Updated European Patent Office Examination Guidelines for AI Inventions
European, News
16/04/2025
The European Patent Office (EPO) has released updated guidelines, effective April 1, 2025, clarifying the patentability of artificial intelligence (AI) and machine learning (ML) inventions. While the core principles remain consistent, the new guidelines emphasize that AI/ML inventions are considered technical and patentable if they are implemented by a computer and contribute to a technical solution.
Read more